植入式心脏复律除颤器：并非评估室性心动过速/颤动治疗效果的最终金标准。 - Suppr | 超能文献

Implantable cardioverter-defibrillators: not the ultimate gold standard for gauging therapy of VT/fibrillation.

作者信息

Singh B N

出版信息

Am J Cardiol. 1994 Jun 15;73(16):1211-3. doi: 10.1016/0002-9149(94)90184-8.

DOI:10.1016/0002-9149(94)90184-8

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Implantable cardioverter-defibrillators: not the ultimate gold standard for gauging therapy of VT/fibrillation.植入式心脏复律除颤器：并非评估室性心动过速/颤动治疗效果的最终金标准。

Am J Cardiol. 1994 Jun 15;73(16):1211-3. doi: 10.1016/0002-9149(94)90184-8.

2

Implantable cardioverter defibrillators in the United States: understanding the benefits and limitations of implantable cardioverter defibrillator therapy based on clinical trial results.

Pacing Clin Electrophysiol. 1998 Nov;21(11 Pt 1):2016-20. doi: 10.1111/j.1540-8159.1998.tb01118.x.

3

Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.多非利特可降低室性心律失常和植入式心脏复律除颤器治疗的频率。

J Cardiovasc Electrophysiol. 2012 Mar;23(3):296-301. doi: 10.1111/j.1540-8167.2011.02183.x. Epub 2011 Sep 28.

4

[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].[室性快速性心律失常的药物治疗：Ⅲ类抗心律失常药物的价值]

Z Kardiol. 1996;85 Suppl 6:97-106.

5

Ventricular tachycardia and ventricular fibrillation.室性心动过速和心室颤动。

Expert Rev Cardiovasc Ther. 2009 Jul;7(7):801-9. doi: 10.1586/erc.09.69.

6

Use of implantable cardioverter-defibrillators.植入式心脏复律除颤器的使用。

Future Cardiol. 2010 Nov;6(6):859-70. doi: 10.2217/fca.10.99.

7

Proarrhythmias and antiarrhythmias: two sides of the same coin.

Heart Rhythm. 2005 Sep;2(9):957-9. doi: 10.1016/j.hrthm.2005.06.003.

8

[Primary and secondary prevention of sudden cardiac death].[心脏性猝死的一级和二级预防]

Pol Arch Med Wewn. 2006 Jan;115(1):65-72.

9

Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".心力衰竭中的抗心律失常药物或植入式心脏复律除颤器：“脆弱的心脏”

Am J Cardiol. 1999 Mar 11;83(5B):83D-87D. doi: 10.1016/s0002-9149(98)01039-x.

10

Predictors of device activation for ventricular arrhythmias and survival in patients with implantable pacemakers/defibrillators. CADENCE Investigators.植入式起搏器/除颤器患者室性心律失常的设备激活预测因素及生存情况。CADENCE研究组。

Pacing Clin Electrophysiol. 1994 Sep;17(9):1487-98. doi: 10.1111/j.1540-8159.1994.tb01513.x.

引用本文的文献

1

Sudden Electrical Death.猝死

Curr Treat Options Cardiovasc Med. 1999 Jun;1(1):91-96. doi: 10.1007/s11936-999-0011-y.

2

Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.胺碘酮：不断拓展的抗心律失常作用及慢性治疗患者的随访方法

Clin Cardiol. 1997 Jul;20(7):608-18. doi: 10.1002/clc.4960200706.

3

Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.索他洛尔的右旋异构体d-索他洛尔的药效学、药代动力学及抗心律失常特性。

Drugs. 1995 May;49(5):664-79. doi: 10.2165/00003495-199549050-00003.